AU2021299504A1 - Compounds having anticancer activity - Google Patents

Compounds having anticancer activity Download PDF

Info

Publication number
AU2021299504A1
AU2021299504A1 AU2021299504A AU2021299504A AU2021299504A1 AU 2021299504 A1 AU2021299504 A1 AU 2021299504A1 AU 2021299504 A AU2021299504 A AU 2021299504A AU 2021299504 A AU2021299504 A AU 2021299504A AU 2021299504 A1 AU2021299504 A1 AU 2021299504A1
Authority
AU
Australia
Prior art keywords
group
alkyl
heteroaryl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021299504A
Other languages
English (en)
Inventor
Connor CHAIN
Zemer Gitai
Hahn Kim
James K. Martin
Joshua D. Rabinowitz
Joseph P. SHEEHAN
Xincheng XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of AU2021299504A1 publication Critical patent/AU2021299504A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021299504A 2020-07-02 2021-07-01 Compounds having anticancer activity Pending AU2021299504A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047612P 2020-07-02 2020-07-02
US63/047,612 2020-07-02
PCT/US2021/040171 WO2022006447A1 (en) 2020-07-02 2021-07-01 Compounds having anticancer activity

Publications (1)

Publication Number Publication Date
AU2021299504A1 true AU2021299504A1 (en) 2023-02-02

Family

ID=79314944

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021299504A Pending AU2021299504A1 (en) 2020-07-02 2021-07-01 Compounds having anticancer activity
AU2021301264A Pending AU2021301264A1 (en) 2020-07-02 2021-07-01 Compounds having antibacterial activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021301264A Pending AU2021301264A1 (en) 2020-07-02 2021-07-01 Compounds having antibacterial activity

Country Status (7)

Country Link
US (2) US20230295164A1 (https=)
EP (2) EP4175953A4 (https=)
JP (2) JP2023535527A (https=)
CN (2) CN115867354B (https=)
AU (2) AU2021299504A1 (https=)
CA (2) CA3183770A1 (https=)
WO (2) WO2022006432A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963959B2 (en) * 2021-08-17 2024-04-23 Southwest Research Institute Inhibitors for coronavirus
WO2024077235A2 (en) * 2022-10-07 2024-04-11 The Trustees Of Princeton University Dihydrofolate reductase inhibitors for anti-biotic resistant infections
CN118047780A (zh) * 2022-11-09 2024-05-17 中国医学科学院药物研究所 一类喹唑啉杂环化合物及其抗感染和抗肿瘤的应用
CN119661535B (zh) * 2023-09-21 2026-03-20 中国医学科学院药物研究所 7H-吡咯并[3,2-f]喹唑啉衍生物及其抗感染应用
WO2025194625A1 (zh) * 2024-03-22 2025-09-25 深圳湾实验室坪山生物医药研发转化中心 结核病的预防与治疗
WO2025195460A1 (zh) * 2024-03-22 2025-09-25 深圳湾实验室坪山生物医药研发转化中心 稠环衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45427B1 (en) * 1976-07-09 1982-08-25 American Home Prod Pyrrold 3,2if quinazoline-1,3-diamine and related compounds
US4118561A (en) * 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
US7253177B2 (en) * 2004-10-22 2007-08-07 United States Of America As Represented By The Secretary Of The Army Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives
US9920058B2 (en) * 2013-05-06 2018-03-20 Georgia Tech Research Corporation Molecules with potent DHFR binding affinity and antibacterial activity
EP3010923A4 (en) * 2013-06-20 2016-12-14 Univ Oregon Health & Science PYRROLOCHINAZOLINVERBINDUNGEN
WO2015173802A1 (en) * 2014-05-11 2015-11-19 Tel Hashomer Medical Research Infrastructure And Services Ltd. Par-1 based therapeutic conjugates and uses thereof
US11077109B2 (en) * 2017-08-01 2021-08-03 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
US20210161900A1 (en) * 2018-04-30 2021-06-03 Duke University Compositions and methods for the treatment of senescent tumor cells
CN114514230A (zh) * 2019-08-20 2022-05-17 希望之城 Mettl16抑制剂及其用途

Also Published As

Publication number Publication date
EP4175958A1 (en) 2023-05-10
CA3183776A1 (en) 2022-01-06
JP2023532128A (ja) 2023-07-26
EP4175953A4 (en) 2024-08-14
CN115867354B (zh) 2025-08-26
CN116234808A (zh) 2023-06-06
AU2021301264A1 (en) 2023-02-02
EP4175953A1 (en) 2023-05-10
JP2023535527A (ja) 2023-08-17
US20230295164A1 (en) 2023-09-21
CN116234808B (zh) 2025-11-14
EP4175958A4 (en) 2024-07-17
WO2022006447A1 (en) 2022-01-06
US20230242540A1 (en) 2023-08-03
CN115867354A (zh) 2023-03-28
CA3183770A1 (en) 2022-01-06
WO2022006432A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
AU2021299504A1 (en) Compounds having anticancer activity
Adams et al. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
WO2008030373A2 (en) L- oddc prodrugs for cancer
WO2016130271A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
JP4814245B2 (ja) 低酸素選択性抗腫瘍剤としてのスルホニルヒドラジンのリン酸含有プロドラッグ
KR20080091134A (ko) 술린닥의 유도체,이의 용도 및 제조방법
EP4261211A1 (en) Dihydroisoquinolinone derivative and application thereof
WO2021062168A1 (en) Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
US20030092637A1 (en) Novel compounds
EP1144423B1 (en) Bis-terpyridine-platinum(ii) complexes
RU2068843C1 (ru) 2-/3-(2-хлорэтил)-3-нитрозоуреидо/-1,3-пропандиол, обладающий противоопухолевой активностью
DE3323316A1 (de) Bis-(2,2-dimethyl-1-aziridinyl)-phosphinsaeure -amide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
HUP0103262A2 (hu) Platina-komplex vegyületeket tartalmazó gyógyszer valamint alkalmazása
WO2025247236A1 (en) Pt (iv) chemotherapeutic prodrug and controlled release thereof for treatment of tumors
CA3102434A1 (en) Selective a2a receptor antagonist
WO2025007955A1 (en) Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) inhibitor combinations and uses thereof
RU2807611C2 (ru) Ингибитор, представляющий собой производное пиридазина, способ его получения и его применение
EP3596054A1 (en) 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments
EP0139023B1 (de) 5-Fluoruracilnitroxylderivate
WO2024178335A2 (en) Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
RU2179555C1 (ru) 5-оксиметил-5-[3-(2-хлорэтил)-3-нитрозоуреидо]-2-циклогексил-1,3-диоксан, обладающий противоопухолевой активностью
KR20250006580A (ko) 화합물, 이를 포함한 조성물 및 이를 이용한 광역학 진단 또는 치료 방법
WO2025177173A1 (en) Polymers useful for conjugating to antibodies and therapeutic uses thereof